Skip to main content
Top
Published in: Neurology and Therapy 2/2023

Open Access 10-02-2023 | Care | ORIGINAL RESEARCH

Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis

Authors: Brett Hauber, Russ Paulsen, Holly B. Krasa, George Vradenburg, Meryl Comer, Leigh F. Callahan, John Winfield, Michele Potashman, Ann Hartry, Daniel Lee, Hilary Wilson, Deborah L. Hoffman, Dan Wieberg, Ian N. Kremer, Geraldine A. Taylor, James M. Taylor, Debra Lappin, Allison D. Martin, Terry Frangiosa, Virginia Biggar, Christina Slota, Carla Romano, Dana B. DiBenedetti

Published in: Neurology and Therapy | Issue 2/2023

Login to get access

Abstract

Introduction

In this phase of the ongoing What Matters Most study series, designed to evaluate concepts that are meaningful to people affected by Alzheimer’s disease (AD), we quantified the importance of symptoms, impacts, and outcomes of AD to people at risk for or with AD and care partners of people with AD.

Methods

We administered a web-based survey to individuals at risk for or with AD (Group 1: unimpaired cognition with evidence of AD pathology; Group 2: AD risk factors and subjective cognitive complaints/mild cognitive impairment; Group 3: mild AD) and to care partners of individuals with moderate AD (Group 4) or severe AD (Group 5). Respondents rated the importance of 42 symptoms, impacts, and outcomes on a scale ranging from 1 (“not at all important”) to 5 (“extremely important”).

Results

Among the 274 respondents (70.4% female; 63.1% white), over half of patient respondents rated all 42 items as “very important” or “extremely important,” while care partners rated fewer items as “very important” or “extremely important.” Among the three patient groups, the minimum (maximum) mean importance rating for any item was 3.4 (4.6), indicating that all items were at least moderately to very important. Among care partners of people with moderate or severe AD, the minimum (maximum) mean importance rating was 2.1 (4.4), indicating that most items were rated as at least moderately important. Overall, taking medications correctly, not feeling down or depressed, and staying safe had the highest importance ratings among both patients and care partners, regardless of AD phase.

Conclusion

Concepts of importance to individuals affected by AD go beyond the common understanding of “cognition” or “function” alone, reflecting a desire to maintain independence, overall physical and mental health, emotional well-being, and safety. Preservation of these attributes may be key to understanding whether interventions deliver clinically meaningful outcomes.
Appendix
Available only for authorised users
Literature
5.
go back to reference Hauber B, DiBenedetti D, Vradenburg G, Callahan L, Potashman M, Krasa H, et al. Identifying what matters to people with and at risk for Alzheimer's disease and their care partners: concept elicitation and item development. Presented at the 12th Clinical Trials in Alzheimer's Disease Meeting; 4 Dec–7 Dec 2019. San Diego, California. Hauber B, DiBenedetti D, Vradenburg G, Callahan L, Potashman M, Krasa H, et al. Identifying what matters to people with and at risk for Alzheimer's disease and their care partners: concept elicitation and item development. Presented at the 12th Clinical Trials in Alzheimer's Disease Meeting; 4 Dec–7 Dec 2019. San Diego, California.
6.
14.
15.
go back to reference Hartry A, Menne H, Wronski S, Paulson R, Callahan L, Potashman M, et al. Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's Disease. Presented at the Alzheimer's Association Virtual International Conference; 27 Jul–30 Jul 2020. Hartry A, Menne H, Wronski S, Paulson R, Callahan L, Potashman M, et al. Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's Disease. Presented at the Alzheimer's Association Virtual International Conference; 27 Jul–30 Jul 2020.
Metadata
Title
Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis
Authors
Brett Hauber
Russ Paulsen
Holly B. Krasa
George Vradenburg
Meryl Comer
Leigh F. Callahan
John Winfield
Michele Potashman
Ann Hartry
Daniel Lee
Hilary Wilson
Deborah L. Hoffman
Dan Wieberg
Ian N. Kremer
Geraldine A. Taylor
James M. Taylor
Debra Lappin
Allison D. Martin
Terry Frangiosa
Virginia Biggar
Christina Slota
Carla Romano
Dana B. DiBenedetti
Publication date
10-02-2023
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 2/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-023-00445-0

Other articles of this Issue 2/2023

Neurology and Therapy 2/2023 Go to the issue